Research graph
References from Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges. Local targets link to admitted publications; unresolved targets remain external evidence.
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
10.1016/s0065-2571(00)00013-3 · 2001 · External reference
Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications
10.1155/2014/852748 · 2014 · External reference
Gene amplification in cancer
10.1016/j.tig.2006.06.007 · 2006 · External reference
Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities
10.1186/s12964-023-01264-4 · 2023 · External reference
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a Zirconium-89 labeled therapeutic antibody, Avelumab
10.1177/1536012119829986 · 2019 · External reference
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
10.1007/s00259-017-3663-y · 2017 · External reference
Clinical implications of intratumor heterogeneity: challenges and opportunities
10.1007/s00109-020-01874-2 · 2020 · External reference
Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT
10.7150/thno.13502 · 2016 · External reference
Molecular imaging biomarkers for early cancer detection: a systematic review of emerging technologies and clinical applications
2024 · External reference
Triple-negative breast cancer: promising prognostic biomarkers currently in development
10.1080/14737140.2021.1840984 · 2021 · External reference
A comparison of accuracy of planar and evolution SPECT/CT bone imaging in differentiating benign from metastatic bone lesions
2017 · External reference
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials
10.1016/j.esmoop.2021.100171 · 2021 · External reference
The predictive value of pretherapy [(68)Ga]Ga-DOTA-TATE PET and biomarkers in [(177)Lu]Lu-PRRT tumor dosimetry
10.1007/s00259-023-06252-x · 2023 · External reference
(89)Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression
10.2967/jnumed.120.250720 · 2021 · External reference
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
10.1038/s41416-022-02031-x · 2023 · External reference
Molecular imaging supports the development of multispecific cancer antibodies
10.1038/s41571-024-00946-3 · 2024 · External reference
Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases
10.1002/med.20002 · 2004 · External reference
Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine
10.1021/cbmi.4c00030 · 2024 · External reference
Radiopharmaceutical development of radiolabelled peptides
10.1007/s00259-011-2001-z · 2012 · External reference
An Evans blue-modified melanin-targeting theranostic agent for improved PET imaging and radionuclide therapy of malignant melanoma
2026 · External reference
Growth factor receptors: promising drug targets in cancer
10.4103/2394-4722.163151 · 2015 · External reference
Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens
10.1309/ajcpt41tcbuevdqc · 2015 · External reference
Imaging of HER2 with [(89)Zr]pertuzumab in response to T-DM1 therapy
2019 · External reference
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
10.1158/0008-5472.can-04-4472 · 2005 · External reference
(18)F-nanobody for PET imaging of HER2 overexpressing tumors
10.1016/j.nucmedbio.2016.01.002 · 2016 · External reference
Evaluation of [(89)Zr]Zr-DFO-2Rs15d nanobody for imaging of HER2-positive breast Cancer
10.1021/acs.molpharmaceut.3c00360 · 2023 · External reference
Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies
10.3390/ijms221910745 · 2021 · External reference
Tumor imaging using a picomolar affinity HER2 binding affibody molecule
10.1158/0008-5472.can-05-3521 · 2006 · External reference
Direct intra-patient comparison of scaffold protein-based tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for imaging of HER2-positive breast cancer
10.3390/cancers15123149 · 2023 · External reference
Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer
10.2967/jnumed.111.093047 · 2012 · External reference
Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging
10.1007/s00259-011-2016-5 · 2012 · External reference
An improved (99m)Tc-HYNIC-(Ser)(3)-LTVSPWY peptide with EDDA/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor
10.1016/j.ejmech.2017.12.037 · 2018 · External reference
Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas
10.1158/1078-0432.ccr-07-0160 · 2007 · External reference
Human epidermal growth factor receptor 2-targeting [(68)Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast cancer
10.2967/jnumed.122.265364 · 2023 · External reference
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
10.2967/jnumed.113.131243 · 2014 · External reference
Unresolved reference
2017 · External reference
(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
10.18632/oncotarget.24965 · 2018 · External reference
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
10.18632/oncotarget.4672 · 2015 · External reference
[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
10.1007/s00259-019-04555-6 · 2020 · External reference
Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models
10.2967/jnumed.118.216069 · 2019 · External reference
Facile labelling of an anti-epidermal growth factor receptor nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET
10.1007/s00259-010-1700-1 · 2011 · External reference
G protein-coupled receptors in cancer
10.3390/ijms17081320 · 2016 · External reference
Somatostatin receptor SPECT
10.1007/s00259-011-2019-2 · 2012 · External reference
Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review
10.1097/rlu.0000000000004670 · 2023 · External reference
(68)Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis
10.2967/jnumed.117.191197 · 2017 · External reference
[(68)Ga]Ga-DOTA-TOC: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging
10.3390/ph13030038 · 2020 · External reference
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors
10.2967/jnumed.111.091165 · 2011 · External reference
Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: a retrospective analysis in neuroendocrine tumor patients
10.18632/oncotarget.27695 · 2020 · External reference
Whole-body 68Ga-DOTANOC PET/MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients
10.1097/rlu.0000000000001753 · 2017 · External reference
Does 68Ga-DOTA-NOC-PET/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?
10.1097/mnm.0000000000001248 · 2020 · External reference
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid
10.1097/mnm.0b013e32832999c1 · 2009 · External reference
Head-to-head comparison between [(68)Ga]Ga-DOTA-NOC and [(18)F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas
10.1007/s00259-024-06622-z · 2024 · External reference
Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis in the era of somatostatin receptor PET imaging
10.3390/cancers17121937 · 2025 · External reference
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
10.1016/j.ejca.2012.10.018 · 2013 · External reference
Upregulation of key molecules for targeted imaging and therapy
10.2967/jnumed.115.165092 · 2016 · External reference
Early over-expression of GRP receptors in prostatic carcinogenesis
10.1002/pros.22743 · 2014 · External reference
Radiolabeled bombesin derivatives for preclinical oncological imaging
10.1016/j.biopha.2016.12.083 · 2017 · External reference
Radiolabeled bombesin analogs
10.3390/cancers13225766 · 2021 · External reference
Bombesin receptor antagonists may be preferable to agonists for tumor targeting
10.2967/jnumed.107.045054 · 2008 · External reference
Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer
10.1016/j.euo.2018.08.011 · 2019 · External reference
Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study
10.2967/jnumed.122.263889 · 2023 · External reference
Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy
10.3390/cancers15184537 · 2023 · External reference
Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer
10.3892/ol.2016.4699 · 2016 · External reference
Appropriate use criteria for prostate-specific membrane antigen PET imaging
10.2967/jnumed.121.263262 · 2022 · External reference
Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
10.1186/s40644-019-0211-y · 2019 · External reference
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer
10.1007/s11307-015-0866-0 · 2015 · External reference
The performance of FDA-approved PET imaging agents in the detection of prostate cancer
10.3390/biomedicines10102533 · 2022 · External reference
First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
10.1007/s00259-018-4096-y · 2019 · External reference
PSMA-targeted radiolabeled peptide for imaging and therapy in prostate cancer: preclinical evaluation of biodistribution and therapeutic efficacy
2025 · External reference
The role of 18F PSMA-1007 PET/CT in the staging and detection of recurrence of prostate cancer, a scoping review
10.3390/cancers17061049 · 2025 · External reference
Application of 18F-PSMA-1007 PET/MR imaging in early biochemical recurrence of prostate cancer: results of a prospective study of 60 patients with very Low PSA levels ≤ 0.5 ng/mL
10.3390/cancers15164185 · 2023 · External reference
Evaluation of preoperative ProstaScint scans in the prediction of nodal disease
10.1038/sj.pcan.4500570 · 2002 · External reference
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer
10.1002/pros.20367 · 2006 · External reference
PSMA-directed theranostics in prostate cancer
10.3390/biomedicines13081837 · 2025 · External reference
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
10.1186/s13550-016-0164-0 · 2016 · External reference
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
10.1158/1078-0432.ccr-05-0826 · 2005 · External reference
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
10.1186/s13550-015-0104-4 · 2015 · External reference
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
10.1002/cncr.24795 · 2010 · External reference
A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer
10.2967/jnumed.115.156729 · 2015 · External reference
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen
10.1136/bmj.285.6353.1447 · 1982 · External reference
Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer
10.1200/jco.1991.9.4.631 · 1991 · External reference
Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging
1998 · External reference
Advancements in colorectal cancer detection: the role of immuno-positron emission tomography, immuno-single-photon emission computed tomography, and machine learning applications
10.1002/jim4.16 · 2024 · External reference
Biopharmaceutical benchmarks 2022
10.1038/s41587-022-01582-x · 2022 · External reference
(99m)Tc-Arcitumomab
2004 · External reference
Preliminary clinical application of RGD-containing peptides as PET radiotracers for imaging tumors
2022 · External reference
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man
10.1158/1078-0432.ccr-06-0266 · 2006 · External reference
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck
10.1158/1078-0432.ccr-07-0528 · 2007 · External reference
PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression
2006 · External reference
Alpha-v beta-3 integrin expression in normal and atherosclerotic artery
10.1161/01.res.77.6.1129 · 1995 · External reference
Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis
10.1016/s0002-9440(10)63293-2 · 2004 · External reference
Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT
10.7150/thno/v01p0058 · 2011 · External reference
Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy
10.1016/j.peptides.2020.170385 · 2020 · External reference
The application value of 18F-Alfatide-RGD PET/CT in the preliminary diagnosis of patients with non-small cell lung cancer
10.1007/s10967-022-08496-7 · 2022 · External reference
A pilot study of (18)F-Alfatide PET/CT imaging for detecting lymph node metastases in patients with non-small cell lung cancer
10.1038/s41598-017-03296-6 · 2017 · External reference
Potential (18)F-RGD PET/CT and DCE-MRI imaging-based biomarkers for postoperative survival prediction among patients with newly diagnosed glioblastoma treated with bevacizumab and chemoradiotherapy
2022 · External reference
Combined (18)F-FDG and (18)F-Alfatide II PET may predict luminal B (HER2 negative) subtype and nonluminal subtype of invasive breast cancer
10.1021/acs.molpharmaceut.2c00547 · 2022 · External reference
68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer
10.2967/jnumed.115.160648 · 2015 · External reference
Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT can discriminate uncommon meningioma mimicking high-grade glioma
10.1097/rlu.0000000000002233 · 2018 · External reference
Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine-glycine-aspartate) strategies
10.3390/ph17111556 · 2024 · External reference
Targeting folate receptor alpha for cancer treatment
10.18632/oncotarget.9651 · 2016 · External reference
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals
10.1016/s0969-8051(03)00080-5 · 2003 · External reference
Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging
10.1021/bc9500709 · 1996 · External reference
Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors
2006 · External reference
Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative
10.1021/bc800356r · 2008 · External reference
[18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting
10.1021/bc200660z · 2012 · External reference
Folate-PEG-NOTA-Al(18)F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors
10.1021/acs.molpharmaceut.7b00415 · 2017 · External reference
Preoperative [(18)F]fluoro-PEG-folate PET/CT in advanced stage epithelial ovarian cancer: a safety and feasibility study
10.1016/j.nucmedbio.2024.108952 · 2024 · External reference
(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
10.1038/s41591-018-0255-8 · 2018 · External reference
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
10.1136/jitc-2023-007659 · 2024 · External reference
First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients
10.2967/jnumed.121.262045 · 2022 · External reference
Assessment of PD-L1 expression in non-small cell lung cancers using [(68)Ga]Ga-DOTA-WL12 PET/CT
10.1002/smtd.202400358 · 2024 · External reference
Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma
10.1016/j.drup.2025.101202 · 2025 · External reference
Synthesis and preclinical evaluation of a (68)Ga-labeled adnectin, (68)Ga-BMS-986192, as a PET agent for imaging PD-L1 expression
10.2967/jnumed.120.258384 · 2021 · External reference
Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer (18)F-BMS-986192
10.2967/jnumed.119.241364 · 2020 · External reference
Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression
10.2967/jnumed.117.199596 · 2018 · External reference
Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities
10.3389/or.2025.1617487 · 2025 · External reference
Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents?
10.1155/2022/3948873 · 2022 · External reference
FAPI-PET/CT in cancer imaging: a potential novel molecule of the century
2022 · External reference
A tumor-imaging method targeting cancer-associated fibroblasts
10.2967/jnumed.118.210435 · 2018 · External reference
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [(18)F]FDG in gynaecological malignancies: systematic literature review and meta-analysis
10.1007/s00259-025-07277-0 · 2025 · External reference
Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis
10.1007/s00330-024-10843-z · 2024 · External reference
Diagnostic performance of radiolabelled FAPI versus [(18)F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis
10.3390/ijms26051978 · 2025 · External reference
The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis
10.21037/qims-2025-1196 · 2026 · External reference
Revealing the hidden: a systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions
10.1007/s00259-025-07576-6 · 2026 · External reference
Comparative diagnostic efficacy of 18F-FDG and FAPI PET/CT in primary liver cancers: a systematic review and meta-analysis
10.4103/jcrt.jcrt_1144_25 · 2025 · External reference
Diagnostic performance of FAPI PET/CT vs. (18)F-FDG PET/CT in evaluation of liver tumors: a systematic review and Meta-analysis
2024 · External reference
Diagnostic value of (18)F-FDG and (68)Ga-FAPI in head and neck cancers: a systematic review and meta-analysis
2025 · External reference
Diagnostic accuracy of [(68)Ga]Ga labeled fibroblast-activation protein inhibitors in detecting head and neck cancer lesions using positron emission tomography: a systematic review and a meta-analysis
10.3390/ph16121664 · 2023 · External reference
Comparison of 68Ga-FAPI PET CT/MRI and 18F-FDG PET/CT in metastatic lesions of gynecological cancers: a systematic review and head-to-head meta-analysis
10.1177/02841851241297836 · 2025 · External reference
Head to head comparison of (68)Ga-FAPI PET/CT with (18)F-FDG PET/CT in primary and metastatic lesions of gastric tumor: a systematic review and meta-analysis
2024 · External reference
The role of FAPI PET/CT in patients with lymphoma: a systematic review
10.3389/fnume.2025.1589903 · 2025 · External reference
Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET/CT
10.1007/s12149-021-01673-w · 2021 · External reference
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
10.1136/annrheumdis-2020-217408 · 2020 · External reference
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
10.1007/s00259-010-1473-6 · 2010 · External reference
Head-to-head comparison of (68)Ga-PSMA-11 and (18)F-FDG in delayed PET/CT imaging in prostate cancer diagnosis
2025 · External reference
Affibody molecules as targeting vectors for PET imaging
10.3390/cancers12030651 · 2020 · External reference
A biodegradable D-π-A structured hemicyanine for constructing tumor-targeted nanoplatform by Cu-64 PET/NIR-II fluorescent/photoacoustic imaging-guided photodynamic and photothermal therapy
2026 · External reference
Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells
10.3109/1061186x.2015.1009075 · 2015 · External reference
A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors
10.1016/j.nucmedbio.2013.07.004 · 2013 · External reference
Albumin-conjugation enables improved tumor targeting of aptamers via SPECT imaging
10.1016/j.omtn.2025.102483 · 2025 · External reference
A novel (68)Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors
10.1016/j.bioorg.2023.106785 · 2023 · External reference
Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-Low breast cancer with [(68)Ga]Ga-ABY-025: results from a pilot study
10.2967/jnumed.123.266847 · 2024 · External reference
Imaging properties and tumor targeting of (68)Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients
10.3390/biomedicines10112899 · 2022 · External reference
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT
10.1007/s00259-015-3232-1 · 2016 · External reference
Evaluating the diagnostic utility of [68Ga]Ga-Pentixafor in solid tumors: a systematic review
10.1007/s12149-025-02093-w · 2025 · External reference
Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer
1996 · External reference
Diagnostic use of radiolabeled antibodies for cancer
1995 · External reference
(68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer
10.2967/jnumed.119.227967 · 2019 · External reference
[(68)Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
10.1016/s1470-2045(25)00299-2 · 2025 · External reference
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
10.1002/cncr.24795 · ExternalCitation · doi-reference
Advancements in colorectal cancer detection: the role of immuno-positron emission tomography, immuno-single-photon emission computed tomography, and machine learning applications
10.1002/jim4.16 · ExternalCitation · doi-reference
Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases
10.1002/med.20002 · ExternalCitation · doi-reference
A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer
10.1002/pros.20367 · ExternalCitation · doi-reference
Early over-expression of GRP receptors in prostatic carcinogenesis
10.1002/pros.22743 · ExternalCitation · doi-reference
Assessment of PD-L1 expression in non-small cell lung cancers using [(68)Ga]Ga-DOTA-WL12 PET/CT
10.1002/smtd.202400358 · ExternalCitation · doi-reference
Clinical implications of intratumor heterogeneity: challenges and opportunities
10.1007/s00109-020-01874-2 · ExternalCitation · doi-reference
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging
10.1007/s00259-010-1473-6 · ExternalCitation · doi-reference
Facile labelling of an anti-epidermal growth factor receptor nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET
10.1007/s00259-010-1700-1 · ExternalCitation · doi-reference
Radiopharmaceutical development of radiolabelled peptides
10.1007/s00259-011-2001-z · ExternalCitation · doi-reference
Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging
10.1007/s00259-011-2016-5 · ExternalCitation · doi-reference
Somatostatin receptor SPECT
10.1007/s00259-011-2019-2 · ExternalCitation · doi-reference
Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT
10.1007/s00259-015-3232-1 · ExternalCitation · doi-reference
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer
10.1007/s00259-017-3663-y · ExternalCitation · doi-reference
First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
10.1007/s00259-018-4096-y · ExternalCitation · doi-reference
[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
10.1007/s00259-019-04555-6 · ExternalCitation · doi-reference
The predictive value of pretherapy [(68)Ga]Ga-DOTA-TATE PET and biomarkers in [(177)Lu]Lu-PRRT tumor dosimetry
10.1007/s00259-023-06252-x · ExternalCitation · doi-reference
Head-to-head comparison between [(68)Ga]Ga-DOTA-NOC and [(18)F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas
10.1007/s00259-024-06622-z · ExternalCitation · doi-reference
Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [(18)F]FDG in gynaecological malignancies: systematic literature review and meta-analysis
10.1007/s00259-025-07277-0 · ExternalCitation · doi-reference
Revealing the hidden: a systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions
10.1007/s00259-025-07576-6 · ExternalCitation · doi-reference
Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis
10.1007/s00330-024-10843-z · ExternalCitation · doi-reference
The application value of 18F-Alfatide-RGD PET/CT in the preliminary diagnosis of patients with non-small cell lung cancer
10.1007/s10967-022-08496-7 · ExternalCitation · doi-reference
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer
10.1007/s11307-015-0866-0 · ExternalCitation · doi-reference
Characterization of the benign lesions with increased (68)Ga-FAPI-04 uptake in PET/CT
10.1007/s12149-021-01673-w · ExternalCitation · doi-reference
Evaluating the diagnostic utility of [68Ga]Ga-Pentixafor in solid tumors: a systematic review
10.1007/s12149-025-02093-w · ExternalCitation · doi-reference
A novel (68)Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors
10.1016/j.bioorg.2023.106785 · ExternalCitation · doi-reference
Radiolabeled bombesin derivatives for preclinical oncological imaging
10.1016/j.biopha.2016.12.083 · ExternalCitation · doi-reference
Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma
10.1016/j.drup.2025.101202 · ExternalCitation · doi-reference
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
10.1016/j.ejca.2012.10.018 · ExternalCitation · doi-reference
An improved (99m)Tc-HYNIC-(Ser)(3)-LTVSPWY peptide with EDDA/tricine as co-ligands for targeting and imaging of HER2 overexpression tumor
10.1016/j.ejmech.2017.12.037 · ExternalCitation · doi-reference
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials
10.1016/j.esmoop.2021.100171 · ExternalCitation · doi-reference
Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography/computed tomography imaging of newly diagnosed prostate cancer
10.1016/j.euo.2018.08.011 · ExternalCitation · doi-reference
A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors
10.1016/j.nucmedbio.2013.07.004 · ExternalCitation · doi-reference
(18)F-nanobody for PET imaging of HER2 overexpressing tumors
10.1016/j.nucmedbio.2016.01.002 · ExternalCitation · doi-reference
Preoperative [(18)F]fluoro-PEG-folate PET/CT in advanced stage epithelial ovarian cancer: a safety and feasibility study
10.1016/j.nucmedbio.2024.108952 · ExternalCitation · doi-reference
Albumin-conjugation enables improved tumor targeting of aptamers via SPECT imaging
10.1016/j.omtn.2025.102483 · ExternalCitation · doi-reference
Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy
10.1016/j.peptides.2020.170385 · ExternalCitation · doi-reference
Gene amplification in cancer
10.1016/j.tig.2006.06.007 · ExternalCitation · doi-reference
Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis
10.1016/s0002-9440(10)63293-2 · ExternalCitation · doi-reference
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
10.1016/s0065-2571(00)00013-3 · ExternalCitation · doi-reference
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals
10.1016/s0969-8051(03)00080-5 · ExternalCitation · doi-reference
[(68)Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial
10.1016/s1470-2045(25)00299-2 · ExternalCitation · doi-reference
Combined (18)F-FDG and (18)F-Alfatide II PET may predict luminal B (HER2 negative) subtype and nonluminal subtype of invasive breast cancer
10.1021/acs.molpharmaceut.2c00547 · ExternalCitation · doi-reference
Evaluation of [(89)Zr]Zr-DFO-2Rs15d nanobody for imaging of HER2-positive breast Cancer
10.1021/acs.molpharmaceut.3c00360 · ExternalCitation · doi-reference
Folate-PEG-NOTA-Al(18)F: a new folate based radiotracer for PET imaging of folate receptor-positive tumors
10.1021/acs.molpharmaceut.7b00415 · ExternalCitation · doi-reference
[18F]fluoro-deoxy-glucose folate: a novel PET radiotracer with improved in vivo properties for folate receptor targeting
10.1021/bc200660z · ExternalCitation · doi-reference
Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative
10.1021/bc800356r · ExternalCitation · doi-reference
Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging
10.1021/bc9500709 · ExternalCitation · doi-reference
Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine
10.1021/cbmi.4c00030 · ExternalCitation · doi-reference
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
10.1038/s41416-022-02031-x · ExternalCitation · doi-reference
Molecular imaging supports the development of multispecific cancer antibodies
10.1038/s41571-024-00946-3 · ExternalCitation · doi-reference
Biopharmaceutical benchmarks 2022
10.1038/s41587-022-01582-x · ExternalCitation · doi-reference
(89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
10.1038/s41591-018-0255-8 · ExternalCitation · doi-reference
A pilot study of (18)F-Alfatide PET/CT imaging for detecting lymph node metastases in patients with non-small cell lung cancer
10.1038/s41598-017-03296-6 · ExternalCitation · doi-reference
Evaluation of preoperative ProstaScint scans in the prediction of nodal disease
10.1038/sj.pcan.4500570 · ExternalCitation · doi-reference
Triple-negative breast cancer: promising prognostic biomarkers currently in development
10.1080/14737140.2021.1840984 · ExternalCitation · doi-reference
Does 68Ga-DOTA-NOC-PET/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?
10.1097/mnm.0000000000001248 · ExternalCitation · doi-reference
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid
10.1097/mnm.0b013e32832999c1 · ExternalCitation · doi-reference
Whole-body 68Ga-DOTANOC PET/MRI versus 68Ga-DOTANOC PET/CT in patients with neuroendocrine tumors: a prospective study in 28 patients
10.1097/rlu.0000000000001753 · ExternalCitation · doi-reference
Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT can discriminate uncommon meningioma mimicking high-grade glioma
10.1097/rlu.0000000000002233 · ExternalCitation · doi-reference
Impact of cold somatostatin analog administration on somatostatin receptor imaging: a systematic review
10.1097/rlu.0000000000004670 · ExternalCitation · doi-reference
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
10.1136/annrheumdis-2020-217408 · ExternalCitation · doi-reference
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen
10.1136/bmj.285.6353.1447 · ExternalCitation · doi-reference
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
10.1136/jitc-2023-007659 · ExternalCitation · doi-reference
Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications
10.1155/2014/852748 · ExternalCitation · doi-reference
Could fibroblast activation protein (FAP)-specific radioligands be considered as pan-tumor agents?
10.1155/2022/3948873 · ExternalCitation · doi-reference
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging
10.1158/0008-5472.can-04-4472 · ExternalCitation · doi-reference
Tumor imaging using a picomolar affinity HER2 binding affibody molecule
10.1158/0008-5472.can-05-3521 · ExternalCitation · doi-reference
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
10.1158/1078-0432.ccr-05-0826 · ExternalCitation · doi-reference
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man
10.1158/1078-0432.ccr-06-0266 · ExternalCitation · doi-reference
Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas
10.1158/1078-0432.ccr-07-0160 · ExternalCitation · doi-reference
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck
10.1158/1078-0432.ccr-07-0528 · ExternalCitation · doi-reference
Alpha-v beta-3 integrin expression in normal and atherosclerotic artery
10.1161/01.res.77.6.1129 · ExternalCitation · doi-reference
Comparison of 68Ga-FAPI PET CT/MRI and 18F-FDG PET/CT in metastatic lesions of gynecological cancers: a systematic review and head-to-head meta-analysis
10.1177/02841851241297836 · ExternalCitation · doi-reference
Immuno-PET imaging of the programmed cell death-1 ligand (PD-L1) using a Zirconium-89 labeled therapeutic antibody, Avelumab
10.1177/1536012119829986 · ExternalCitation · doi-reference
Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities
10.1186/s12964-023-01264-4 · ExternalCitation · doi-reference
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
10.1186/s13550-015-0104-4 · ExternalCitation · doi-reference
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
10.1186/s13550-016-0164-0 · ExternalCitation · doi-reference
Intra-individual comparison of (68)Ga-PSMA-11 and (18)F-DCFPyL normal-organ biodistribution
10.1186/s40644-019-0211-y · ExternalCitation · doi-reference
Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer
10.1200/jco.1991.9.4.631 · ExternalCitation · doi-reference
Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens
10.1309/ajcpt41tcbuevdqc · ExternalCitation · doi-reference
(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
10.18632/oncotarget.24965 · ExternalCitation · doi-reference
Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: a retrospective analysis in neuroendocrine tumor patients
10.18632/oncotarget.27695 · ExternalCitation · doi-reference
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
10.18632/oncotarget.4672 · ExternalCitation · doi-reference
Targeting folate receptor alpha for cancer treatment
10.18632/oncotarget.9651 · ExternalCitation · doi-reference
The impact of FAPI PET on staging and management in patients with digestive system tumors: a systematic review and meta-analysis
10.21037/qims-2025-1196 · ExternalCitation · doi-reference
Bombesin receptor antagonists may be preferable to agonists for tumor targeting
10.2967/jnumed.107.045054 · ExternalCitation · doi-reference
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors
10.2967/jnumed.111.091165 · ExternalCitation · doi-reference
Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer
10.2967/jnumed.111.093047 · ExternalCitation · doi-reference
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
10.2967/jnumed.113.131243 · ExternalCitation · doi-reference
A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT/CT imaging of prostate cancer
10.2967/jnumed.115.156729 · ExternalCitation · doi-reference
68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer
10.2967/jnumed.115.160648 · ExternalCitation · doi-reference
Upregulation of key molecules for targeted imaging and therapy
10.2967/jnumed.115.165092 · ExternalCitation · doi-reference
(68)Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis
10.2967/jnumed.117.191197 · ExternalCitation · doi-reference
Synthesis and biologic evaluation of a novel (18)F-labeled adnectin as a PET radioligand for imaging PD-L1 expression
10.2967/jnumed.117.199596 · ExternalCitation · doi-reference
A tumor-imaging method targeting cancer-associated fibroblasts
10.2967/jnumed.118.210435 · ExternalCitation · doi-reference
Affibody-based PET imaging to guide EGFR-targeted cancer therapy in head and neck squamous cell cancer models
10.2967/jnumed.118.216069 · ExternalCitation · doi-reference
(68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer
10.2967/jnumed.119.227967 · ExternalCitation · doi-reference
Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer (18)F-BMS-986192
10.2967/jnumed.119.241364 · ExternalCitation · doi-reference
(89)Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression
10.2967/jnumed.120.250720 · ExternalCitation · doi-reference
Synthesis and preclinical evaluation of a (68)Ga-labeled adnectin, (68)Ga-BMS-986192, as a PET agent for imaging PD-L1 expression
10.2967/jnumed.120.258384 · ExternalCitation · doi-reference
First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients
10.2967/jnumed.121.262045 · ExternalCitation · doi-reference
Appropriate use criteria for prostate-specific membrane antigen PET imaging
10.2967/jnumed.121.263262 · ExternalCitation · doi-reference
Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study
10.2967/jnumed.122.263889 · ExternalCitation · doi-reference
Human epidermal growth factor receptor 2-targeting [(68)Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast cancer
10.2967/jnumed.122.265364 · ExternalCitation · doi-reference
Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-Low breast cancer with [(68)Ga]Ga-ABY-025: results from a pilot study
10.2967/jnumed.123.266847 · ExternalCitation · doi-reference
Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells
10.3109/1061186x.2015.1009075 · ExternalCitation · doi-reference
The role of FAPI PET/CT in patients with lymphoma: a systematic review
10.3389/fnume.2025.1589903 · ExternalCitation · doi-reference
Fibroblast activation protein and the tumour microenvironment: challenges and therapeutic opportunities
10.3389/or.2025.1617487 · ExternalCitation · doi-reference
The performance of FDA-approved PET imaging agents in the detection of prostate cancer
10.3390/biomedicines10102533 · ExternalCitation · doi-reference
Imaging properties and tumor targeting of (68)Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients
10.3390/biomedicines10112899 · ExternalCitation · doi-reference
PSMA-directed theranostics in prostate cancer
10.3390/biomedicines13081837 · ExternalCitation · doi-reference
Affibody molecules as targeting vectors for PET imaging
10.3390/cancers12030651 · ExternalCitation · doi-reference
Radiolabeled bombesin analogs
10.3390/cancers13225766 · ExternalCitation · doi-reference
Direct intra-patient comparison of scaffold protein-based tracers, [(99m)Tc]Tc-ADAPT6 and [(99m)Tc]Tc-(HE)(3)-G3, for imaging of HER2-positive breast cancer
10.3390/cancers15123149 · ExternalCitation · doi-reference
Application of 18F-PSMA-1007 PET/MR imaging in early biochemical recurrence of prostate cancer: results of a prospective study of 60 patients with very Low PSA levels ≤ 0.5 ng/mL
10.3390/cancers15164185 · ExternalCitation · doi-reference
Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy
10.3390/cancers15184537 · ExternalCitation · doi-reference
The role of 18F PSMA-1007 PET/CT in the staging and detection of recurrence of prostate cancer, a scoping review
10.3390/cancers17061049 · ExternalCitation · doi-reference
Somatostatin receptor expression of gastroenteropancreatic neuroendocrine tumors: a comprehensive analysis in the era of somatostatin receptor PET imaging
10.3390/cancers17121937 · ExternalCitation · doi-reference
G protein-coupled receptors in cancer
10.3390/ijms17081320 · ExternalCitation · doi-reference
Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies
10.3390/ijms221910745 · ExternalCitation · doi-reference
Diagnostic performance of radiolabelled FAPI versus [(18)F]FDG PET imaging in hepato-pancreato-biliary oncology: a systematic review and meta-analysis
10.3390/ijms26051978 · ExternalCitation · doi-reference
[(68)Ga]Ga-DOTA-TOC: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging
10.3390/ph13030038 · ExternalCitation · doi-reference
Diagnostic accuracy of [(68)Ga]Ga labeled fibroblast-activation protein inhibitors in detecting head and neck cancer lesions using positron emission tomography: a systematic review and a meta-analysis
10.3390/ph16121664 · ExternalCitation · doi-reference
Integrin targeting and beyond: enhancing cancer treatment with dual-targeting RGD (arginine-glycine-aspartate) strategies
10.3390/ph17111556 · ExternalCitation · doi-reference
Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer
10.3892/ol.2016.4699 · ExternalCitation · doi-reference
Growth factor receptors: promising drug targets in cancer
10.4103/2394-4722.163151 · ExternalCitation · doi-reference
Comparative diagnostic efficacy of 18F-FDG and FAPI PET/CT in primary liver cancers: a systematic review and meta-analysis
10.4103/jcrt.jcrt_1144_25 · ExternalCitation · doi-reference
Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT
10.7150/thno.13502 · ExternalCitation · doi-reference
Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT
10.7150/thno/v01p0058 · ExternalCitation · doi-reference
